A new drug combo for EGFR positive advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two drugs—Becotatug Vedotin (a targeted therapy that delivers chemotherapy directly to EGFR-positive cancer cells) and Pucotenlimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced solid tumors that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be EGFR positive (a high level of a protein called EGFR on the tumor cells).
- You have tried at least one standard treatment that either didn't work or caused side effects you couldn't handle.
- You have a tumor that can be measured on a scan (like a CT or MRI).
- Your blood counts and organ function (liver, kidneys, etc.) must be within a safe range.
- You cannot have active autoimmune disease, uncontrolled infections, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
This trial tests a new combination of a targeted therapy (EGFR-ADC) and an immunotherapy drug before surgery to shrink and control locally advanced throat cancer. It may help make surgery more effective and reduce the chance of recurrence.
This trial tests two new drugs (Becotatug vedotin and Pucotenlimab), with or without radiation, as the first treatment for advanced lung cancer that has a specific protein marker (EGFR). The goal is to see if this combination can shrink tumors and help people live longer without their cancer growing.
This trial tests a new combination of drugs for a type of head and neck cancer that has a specific protein called EGFR. The treatment combines an antibody-drug conjugate, an immunotherapy, and standard chemotherapy. The goal is to see if this combination shrinks or controls the cancer before possible surgery.
This trial tests a new drug combination for advanced bile duct or gallbladder cancer that has not responded to earlier treatments. It aims to see if the combination can shrink tumors and help patients live longer.
This trial tests a combination of two drugs—becotatugvedotin (which targets EGFR on cancer cells) and pucotenlimab (an immunotherapy that helps the immune system fight cancer)—for people with advanced stomach or GEJ cancer that is EGFR-positive and has progressed after one prior treatment. It aims to see if this combo can shrink tumors or slow the cancer's growth.
Hear when a new Advanced Refractory Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.